Person:
TÜRK, HACI MEHMET

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Organizational Unit
Job Title
First Name
HACI MEHMET
Last Name
TÜRK
Name
Email Address
Birth Date

Search Results

Now showing 1 - 2 of 2
  • PublicationMetadata only
    Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy
    (2024-03-01) HATİBOĞLU M. A.; Akdur K.; Sakarcan A.; SEYİTHANOĞLU M. H.; TÜRK H. M.; Sinclair G.; ÖZTANIR M. N.; HATİBOĞLU, MUSTAFA AZİZ; SEYİTHANOĞLU, MEHMET HAKAN; TÜRK, HACI MEHMET; ÖZTANIR, MUSTAFA NAMIK
    Background: The role of Gamma Knife radiosurgery (GKRS) in recurrent glioblastoma remains unclear. The purpose of this study is to evaluate the effects of GKRS in a group of patients with recurrent glioblastoma, focusing on survival and safety. Methods: Patients undergoing GKRS for recurrent glioblastoma between September 2014 and April 2019 were included in this study. Relevant clinical and radiosurgical data, including GKRS-related complications, were recorded and analyzed. Overall survival (OS), local progression free survival (LPFS) and prognostic factors for outcome were thoroughly evaluated. Results: Fifty-three patients were analyzed (24 female, 29 male). The median age was 50 years (range, 19–78 years). The median GKRS treatment volume was 35.01 cm3 (range, 2.38-115.57 cm3). Twenty patients (38%) were treated with single fraction GKRS, while 33 (62%) were treated with GKRS-based hypofractionated stereotactic radiotherapy (HSRT). The median prescription dose for single fraction GKRS, 3-fractions HSRT and 5-fractions HSRT were 16 Gy (range, 10−20 Gy), 27 Gy (range, 18−33 Gy) and 25 Gy (range, 25−30 Gy), respectively. The median LPFS and OS times were 8.1 months and 11.4 months after GKRS, respectively. HSRT and Bevacizumab were associated with improved LPFS, while HSRT alone was associated with longer OS. Conclusion: Our findings suggested that HRST would likely improve LPFS and OS in definite settings; the addition of Bevacizumab to GKRS was associated with increased rates of local control. No major complications were reported. Further prospective studies are warranted to confirm our findings.
  • PublicationMetadata only
    Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
    (2024-04-13) Yildirim M. E.; Karadurmus N.; Okten I. N.; TÜRK H. M.; Urakci Z.; Arslan C.; Celik S.; DANE F.; ŞENDUR M. A. N.; BİLİR C.; et al.; TÜRK, HACI MEHMET
    Backgrounds and Objectives Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).Materials and Methods In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.Results A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (p = 0.848).Conclusion According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.